Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
12.46
-5.48 (-30.54%)
At close: Apr 28, 2026, 4:00 PM EDT
12.46
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Cue Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 27.47 | 9.29 | 5.49 | 1.25 | 14.94 | |
| Revenue Growth (YoY) | 195.75% | 69.16% | 340.96% | -91.67% | 373.68% | |
| Cost of Revenue | 34.84 | 32.9 | 40.8 | 35.3 | 41.35 | |
| Gross Profit | -7.38 | -23.61 | -35.31 | -34.05 | -26.41 | |
| Selling, General & Admin | 19.14 | 17.99 | 16.68 | 19.45 | 17.31 | |
| Operating Expenses | 19.14 | 17.99 | 16.68 | 19.45 | 17.31 | |
| Operating Income | -26.52 | -41.59 | -51.99 | -53.5 | -43.71 | |
| Interest Expense | -0.36 | -0.8 | -1.25 | -0.71 | - | |
| Interest & Investment Income | 0.81 | 1.62 | 2.66 | 0.93 | 0.05 | |
| EBT Excluding Unusual Items | -26.07 | -40.77 | -50.58 | -53.29 | -43.67 | |
| Gain (Loss) on Sale of Assets | -0.03 | 0.09 | -0.16 | 0.28 | - | |
| Pretax Income | -26.1 | -40.67 | -50.73 | -53.01 | -43.67 | |
| Income Tax Expense | 0.5 | - | - | - | 0.5 | |
| Net Income | -26.6 | -40.67 | -50.73 | -53.01 | -44.16 | |
| Net Income to Common | -26.6 | -40.67 | -50.73 | -53.01 | -44.16 | |
| Shares Outstanding (Basic) | 3 | 2 | 2 | 1 | 1 | |
| Shares Outstanding (Diluted) | 3 | 2 | 2 | 1 | 1 | |
| Shares Change (YoY) | 68.18% | 23.11% | 28.35% | 13.95% | 9.05% | |
| EPS (Basic) | -8.42 | -21.66 | -33.26 | -44.61 | -42.35 | |
| EPS (Diluted) | -8.42 | -21.66 | -33.26 | -44.61 | -42.35 | |
| Free Cash Flow | -21.86 | -36.4 | -39.96 | -41.98 | -39.75 | |
| Free Cash Flow Per Share | -6.92 | -19.38 | -26.20 | -35.33 | -38.12 | |
| Gross Margin | -26.86% | -254.21% | - | - | -176.73% | |
| Operating Margin | -96.56% | -447.86% | -947.03% | -4297.35% | -292.56% | |
| Profit Margin | -96.85% | -437.97% | -924.10% | -4257.83% | -295.56% | |
| Free Cash Flow Margin | -79.60% | -391.89% | -727.89% | -3371.65% | -266.04% | |
| EBITDA | -25.56 | -41.2 | -51.44 | -52.58 | -42.45 | |
| EBITDA Margin | -93.07% | - | - | - | -284.14% | |
| D&A For EBITDA | 0.96 | 0.4 | 0.56 | 0.92 | 1.26 | |
| EBIT | -26.52 | -41.59 | -51.99 | -53.5 | -43.71 | |
| EBIT Margin | -96.56% | - | - | - | -292.56% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.